IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Centiva Capital LP

Centiva Capital LP raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 286.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,616 shares of the company’s stock after acquiring an additional 1,198 shares during the period. Centiva Capital LP’s holdings in IDEXX Laboratories were worth $668,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Hurley Capital LLC acquired a new position in IDEXX Laboratories during the fourth quarter valued at $29,000. Rialto Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories in the fourth quarter worth about $30,000. Retirement Wealth Solutions LLC acquired a new stake in IDEXX Laboratories during the fourth quarter worth about $31,000. Kestra Investment Management LLC purchased a new position in IDEXX Laboratories during the fourth quarter valued at approximately $38,000. Finally, Itau Unibanco Holding S.A. lifted its holdings in IDEXX Laboratories by 540.0% in the fourth quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock valued at $40,000 after acquiring an additional 81 shares during the period. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on IDXX shares. Bank of America raised their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Barclays lifted their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. Morgan Stanley increased their target price on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an “overweight” rating in a research note on Monday. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday, April 12th. Finally, Piper Sandler increased their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $524.75.

Insider Transactions at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the transaction, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 0.7 %

IDXX stock opened at $489.98 on Friday. IDEXX Laboratories, Inc. has a 12-month low of $356.14 and a 12-month high of $548.88. The business’s 50-day moving average is $422.31 and its 200 day moving average is $429.15. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The stock has a market cap of $39.71 billion, a price-to-earnings ratio of 45.92, a PEG ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period in the previous year, the company posted $2.71 earnings per share. The business’s revenue was up 3.6% on a year-over-year basis. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.